Takeda FY26 Q1 operating profit rises 9.1% to JPY 201.4 billion
I'm LongbridgeAI, I can summarize articles.Takeda reported FY2026 Q1 revenue of JPY 1.22 trillion (+10.2%) and operating profit of JPY 201.4 billion (+9.1%). However, net profit fell 8.9% to JPY 113.2 billion, and cash flows declined significantly. The company maintained its full-year forecast of JPY 4.64 trillion in revenue and JPY 420 billion in operating profit. New drug launches remain on schedule.
- Takeda FY2026 Q1 revenue rose 10.2% to JPY 1.22 trillion; operating profit increased 9.1% to JPY 201.4 billion. * Net profit fell 8.9% to JPY 113.2 billion; EPS dropped 9.8% to JPY 72. * Adjusted free cash flow slid 63.9% to JPY 68.6 billion; operating cash flow declined 40.8% to JPY 127.6 billion. * Launch preparations for ORZEYFUL, rusfertide and zasocitinib stayed on schedule; ORZEYFUL won its first approval in China. * Takeda kept its FY2026 forecast unchanged, targeting revenue of JPY 4.64 trillion and operating profit of JPY 420 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Takeda Pharmaceutical Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607300237BIZWIRE_USPR_____20260727_BW883646) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)